Published in Hypertension on March 29, 2010
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Cardiac dimensions are largely determined by dietary salt in patients with primary aldosteronism: results of a case-control study. J Clin Endocrinol Metab (2011) 1.64
Global- and renal-specific sympathoinhibition in aldosterone hypertension. Hypertension (2015) 0.96
Body Mass Index Predicts 24-Hour Urinary Aldosterone Levels in Patients With Resistant Hypertension. Hypertension (2016) 0.90
Current challenges in the clinical management of hypertension. Nat Rev Cardiol (2011) 0.89
Aldosterone receptor antagonists: current perspectives and therapies. Vasc Health Risk Manag (2013) 0.88
Management of patients with resistant hypertension: current treatment options. Integr Blood Press Control (2013) 0.84
Aldosteronism and resistant hypertension. Int J Hypertens (2011) 0.83
How can resistant hypertension be identified and prevented? Nat Rev Cardiol (2013) 0.81
Aldosterone and the heart: still an unresolved issue? Front Endocrinol (Lausanne) (2014) 0.79
Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens (2014) 0.79
Cost-Effectiveness of Screening for Primary Aldosteronism and Subtype Diagnosis in the Resistant Hypertensive Patients. Circ Cardiovasc Qual Outcomes (2015) 0.78
Hyperaldosteronism and left ventricular hypertrophy. Hypertension (2010) 0.78
Aldosterone and aldosterone antagonists in cardiac disease: what is known, what is new. Am J Cardiovasc Dis (2011) 0.78
Left ventricular torsion shear angle volume analysis in patients with hypertension: a global approach for LV diastolic function. J Cardiovasc Magn Reson (2014) 0.77
Improved Right Ventricular Performance with Increased Tricuspid Annular Excursion in Athlete's Heart. Front Cardiovasc Med (2015) 0.76
Alterations in vascular function in primary aldosteronism: a cardiovascular magnetic resonance imaging study. J Hum Hypertens (2013) 0.76
Distinctive Risk Factors and Phenotype of Younger Patients With Resistant Hypertension: Age Is Relevant. Hypertension (2017) 0.75
Refractory versus resistant hypertension: Novel distinctive phenotypes. J Nat Sci (2017) 0.75
Clinical characteristics, target organ damage and associate risk factors of resistant hypertension determined by ambulatory blood pressure monitoring in patients aged ≥ 80 years. J Geriatr Cardiol (2017) 0.75
Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr (2005) 46.32
Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med (2004) 4.92
Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. Circulation (1994) 4.52
Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol (2005) 4.20
Left atrial size and the risk of stroke and death. The Framingham Heart Study. Circulation (1995) 4.04
A prospective study of the prevalence of primary aldosteronism in 1,125 hypertensive patients. J Am Coll Cardiol (2006) 3.74
Left atrial volume: a powerful predictor of survival after acute myocardial infarction. Circulation (2003) 3.08
Aldosterone induces a vascular inflammatory phenotype in the rat heart. Am J Physiol Heart Circ Physiol (2002) 2.94
Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med (1992) 2.54
Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension (2002) 2.46
Hyperparathyroidism and the calcium paradox of aldosteronism. Circulation (2005) 2.03
Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab (2000) 2.00
Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens (2004) 1.75
Role of aldosterone in left ventricular hypertrophy in hypertension. Am J Hypertens (2006) 1.71
Salt-sensitive blood pressure in mice with increased expression of aldosterone synthase. Hypertension (2007) 1.70
Evidence for abnormal left ventricular structure and function in normotensive individuals with familial hyperaldosteronism type I. J Clin Endocrinol Metab (2005) 1.68
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care (2007) 1.60
Renin activity and blood pressure in response to chronic episodic hypoxia. Hypertension (1999) 1.55
Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med (2008) 1.53
Primary aldosteronism and hypertensive disease. Hypertension (2003) 1.49
Mineralocorticoids, hypertension, and cardiac fibrosis. J Clin Invest (1994) 1.48
Relationship between plasma and extracellular fluid volume depletion and the antihypertensive effect of chlorothiazide. Circulation (1959) 1.38
Hemodynamic and hypotensive effects of long-term therapy with chlorothiazide. Circulation (1960) 1.37
Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens (2003) 1.35
Blood pressure response to chronic episodic hypoxia: the renin-angiotensin system. J Appl Physiol (1985) (2002) 1.35
Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis (2001) 1.31
Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation (2004) 1.28
Cardiovascular complications in patients with primary aldosteronism. Am J Kidney Dis (1999) 1.24
Plasminogen activator inhibitor-1 deficiency protects against aldosterone-induced glomerular injury. Kidney Int (2006) 1.19
Antifibrotic effects of spironolactone in preventing myocardial fibrosis in systemic arterial hypertension. Am J Cardiol (1993) 1.17
Screening for primary aldosteronism in essential hypertension: diagnostic accuracy of the ratio of plasma aldosterone concentration to plasma renin activity. Clin Chem (2005) 1.17
Alterations of calcium metabolism and of parathyroid function in primary aldosteronism, and their reversal by spironolactone or by surgical removal of aldosterone-producing adenomas. Am J Hypertens (1995) 1.16
Relation of dietary salt and aldosterone to urinary protein excretion in subjects with resistant hypertension. Hypertension (2007) 1.14
Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension (1996) 1.12
Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol (1995) 1.10
Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension (2002) 1.08
Accuracy of biplane long-axis left ventricular volume determined by cine magnetic resonance imaging in patients with regional and global dysfunction. Am J Cardiol (1996) 1.08
High prevalence of primary aldosteronism in the Tayside hypertension clinic population. J Hum Hypertens (2000) 1.01
Diuretics and bone loss in rats with aldosteronism. J Am Coll Cardiol (2005) 0.89
Impact of aldosterone on left ventricular structure and function in young normotensive and mildly hypertensive subjects. Am J Cardiol (2000) 0.79
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA (2003) 97.28
Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension (2003) 63.78
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 23.18
A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med (2015) 19.14
A controlled trial of renal denervation for resistant hypertension. N Engl J Med (2014) 14.22
Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med (2006) 9.40
Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension (2008) 6.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the american heart association. Circulation (2011) 5.26
Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation (2008) 5.26
The relationship between visit-to-visit variability in systolic blood pressure and all-cause mortality in the general population: findings from NHANES III, 1988 to 1994. Hypertension (2011) 5.14
Heart failure, chronic diuretic use, and increase in mortality and hospitalization: an observational study using propensity score methods. Eur Heart J (2006) 4.55
Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension (2009) 4.26
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation (2007) 4.16
Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med (2003) 3.78
Valganciclovir for symptomatic congenital cytomegalovirus disease. N Engl J Med (2015) 3.75
Evidence-based guidelines for cardiovascular disease prevention in women. Circulation (2004) 3.39
Pathogenesis of hypertension. Ann Intern Med (2003) 3.18
The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int (2004) 2.96
Effectiveness-based guidelines for the prevention of cardiovascular disease in women--2011 update: a guideline from the American Heart Association. J Am Coll Cardiol (2011) 2.89
Blood pressure measurement device, number and timing of visits, and intra-individual visit-to-visit variability of blood pressure. J Clin Hypertens (Greenwich) (2012) 2.85
Left ventricular trabeculae: quantification in different cardiac diseases and impact on left ventricular morphological and functional parameters assessed with cardiac magnetic resonance. J Cardiovasc Med (Hagerstown) (2009) 2.84
Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension (2013) 2.83
Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension (2013) 2.74
Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study. Hypertension (2005) 2.69
Long-term follow-up of moderately hypercholesterolemic hypertensive patients following randomization to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). J Clin Hypertens (Greenwich) (2013) 2.64
Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens (2003) 2.54
Efficacy and tolerability of eplerenone and losartan in hypertensive black and white patients. J Am Coll Cardiol (2003) 2.47
Visit-to-Visit Variability of Blood Pressure and Coronary Heart Disease, Stroke, Heart Failure, and Mortality: A Cohort Study. Ann Intern Med (2015) 2.42
Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension (2012) 2.42
Magnetic resonance imaging with 3-dimensional analysis of left ventricular remodeling in isolated mitral regurgitation: implications beyond dimensions. Circulation (2012) 2.37
Atrial natriuretic peptide inhibits transforming growth factor beta-induced Smad signaling and myofibroblast transformation in mouse cardiac fibroblasts. Circ Res (2007) 2.32
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload. J Am Coll Cardiol (2007) 2.21
Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) (2011) 2.11
Effects of losartan or atenolol in hypertensive patients without clinically evident vascular disease: a substudy of the LIFE randomized trial. Ann Intern Med (2003) 2.09
ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses. Arch Intern Med (2009) 2.02
Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol (2009) 2.01
Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov (2002) 1.98
ACCF/AHA 2011 expert consensus document on hypertension in the elderly: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation (2011) 1.97
Capacitative calcium entry contributes to nuclear factor of activated T-cells nuclear translocation and hypertrophy in cardiomyocytes. J Biol Chem (2002) 1.89
Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension (2009) 1.88
Increased dietary sodium is related to severity of obstructive sleep apnea in patients with resistant hypertension and hyperaldosteronism. Chest (2013) 1.88
Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction. Hypertension (2009) 1.82
Estrogen modulates TNF-alpha-induced inflammatory responses in rat aortic smooth muscle cells through estrogen receptor-beta activation. Am J Physiol Heart Circ Physiol (2007) 1.80
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure. Circulation (2010) 1.73
Trends in hypertension prevalence, awareness, treatment, and control among US adults 80 years and older, 1988-2010. J Clin Hypertens (Greenwich) (2014) 1.72
A randomized controlled phase IIb trial of beta(1)-receptor blockade for chronic degenerative mitral regurgitation. J Am Coll Cardiol (2012) 1.69
Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol (2007) 1.69
Characterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med (2008) 1.68
Catheter-based renal denervation for resistant hypertension: rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol (2012) 1.66
Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest (2007) 1.65
Angiotensin II receptor blockade does not improve left ventricular function and remodeling in subacute mitral regurgitation in the dog. J Am Coll Cardiol (2002) 1.65
Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR. Clin J Am Soc Nephrol (2012) 1.62
Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension (2003) 1.61
Relation of torsion and myocardial strains to LV ejection fraction in hypertension. JACC Cardiovasc Imaging (2012) 1.61
Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol (2004) 1.59
Long-term effects of incident diabetes mellitus on cardiovascular outcomes in people treated for hypertension: the ALLHAT Diabetes Extension Study. Circ Cardiovasc Qual Outcomes (2012) 1.59
c-kit is required for cardiomyocyte terminal differentiation. Circ Res (2008) 1.58
Absence of obesity paradox in patients with chronic heart failure and diabetes mellitus: a propensity-matched study. Eur J Heart Fail (2010) 1.55
Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens (2007) 1.54
Protein O-GlcNAcylation: a new signaling paradigm for the cardiovascular system. Am J Physiol Heart Circ Physiol (2008) 1.53
Does albuminuria predict cardiovascular outcome on treatment with losartan versus atenolol in hypertension with left ventricular hypertrophy? A LIFE substudy. J Hypertens (2004) 1.53
Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol (2010) 1.52
Stroke reduction in hypertensive adults with cardiac hypertrophy randomized to losartan versus atenolol: the Losartan Intervention For Endpoint reduction in hypertension study. Hypertension (2004) 1.52
Long-term follow-up of participants with heart failure in the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). Circulation (2011) 1.52
Routine, self-administered, touch-screen, computer-based suicidal ideation assessment linked to automated response team notification in an HIV primary care setting. Clin Infect Dis (2010) 1.51